The collaboration aims at the joint development of technologies for the production of medical isotopes and the marketing and distribution of related isotopes, equipment and services.
AMIC chairman and CEO James Katzaroff said this is a particularly opportune time to begin the distribution of Molybendum-99 (Mo-99) because major suppliers of the isotope are experiencing both scheduled and unscheduled downtimes.
"Additionally, one of the major suppliers of Mo-99 has announced that it will exit the market by 2017 when its reactors reach retirement age," Katzaroff added.
AMIC initially will have exclusive rights for sale and distribution in North America, South America and China.
GSG is the Switzerland-based member of Gamma Service Group International, an innovative provider of advanced services, equipment and solutions for production and handling of radionuclide materials with operations in Switzerland, Germany and Russia.